Nanoimmunotherapy to treat ischaemic heart disease

Area of Science:

• Cardiovascular Medicine
• Immunology
• Nanotechnology

Background:

• Atherosclerosis is a chronic inflammatory disease of large arteries, a leading cause of myocardial infarction and stroke.
• While lipid-lowering therapies are successful, atherosclerosis remains a significant global health threat.
• Recent advances focus on cardiovascular immunopathology, identifying inflammation as a key therapeutic target.

Purpose of the Study:

• To review the shift in therapeutic focus from lipids to inflammation in atherosclerosis treatment.
• To highlight the potential of nanotechnology in developing targeted immunomodulatory treatments.
• To discuss the challenges and future directions for nanoimmunotherapies in cardiovascular disease.

Main Methods:

• Review of clinical trial data, including the CANTOS trial, on anti-inflammatory therapies.
• Analysis of preclinical studies on nanotechnology for targeted immune cell modulation.
• Synthesis of current understanding of atherosclerosis immunopathology.

Main Results:

• The CANTOS trial demonstrated that Interleukin-1 beta (IL-1β) inhibition reduces cardiovascular event recurrence.
• Preclinical research indicates nanotechnology can specifically target innate immune cells for immunomodulation.
• These approaches offer potential for disease regression and prevention of recurrent cardiovascular events.

Conclusions:

• Targeting inflammation, exemplified by IL-1β inhibition, is a validated strategy for cardiovascular disease treatment.
• Nanoimmunotherapies represent a promising frontier for developing more effective treatments for atherosclerosis.
• Clinical translation of nanoimmunotherapies for ischaemic heart disease requires further research and development.